Blood-Levels of S-Adenosylmethionine in Schizophrenia

Andreoli, V. M.; Maffei, F.

doi:10.1016/s0140-6736(75)92157-1

Cited by 21 publications

(14 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results do not confirm the report by Andreoli and Maffei (1975) of significantly lower levels of blood SAMe in acute schizo phrenics in comparison with normal subjects. Indeed, our acute schizophrenics showed higher blood levels of SAMe as compared both with chronic and with normal controls, and the difference was statistically significant in the first case.…”

Section: Discussioncontrasting

confidence: 99%

“…No signifi cant difference was found. Andreoli and Maffei (1975) determined SAMe blood levels in 14 schizophrenics (7 acute and 7 chronic), 6 depressives and 15 normal controls. Acute schizo phrenics showed significantly lower concentra tions than controls, suggesting either an exces sive utilization, according to Harley-Mason's hypothesis, or a reduced synthesis, as proposed by Levi and Waxman (1975), of the methyl donor.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Blood Levels of S-Adenosylmethionine in Unmedicated Schizophrenic and Depressive Patients

Maj¹,

Zizolfi²,

Vecchio³

1981

Neuropsychobiology

View full text Add to dashboard Cite

S-Adenosylmethionine blood levels have been estimated by a specific radioenzymatic method in 52 schizophrenics and 12 depressives, diagnosed and subtyped according to ICD-9 and compared with 38 normal controls. Previous reports of significantly lower levels of blood SAMe in acute schizophrenics in comparison with normal subjects could not be confirmed in this study. Indeed, acute schizophrenics showed higher mean SAMe blood levels as compared both with chronic and with normal controls. No significant difference has been found comparing both schizophrenics as a whole and depressives with normal controls. This investigation aims to bring a contribution to the recently started critical revision of transmethylation hypothesis of schizophrenia.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Blood Levels of S-Adenosylmethionine in Unmedicated Schizophrenic and Depressive Patients

Maj¹,

Zizolfi²,

Vecchio³

1981

Neuropsychobiology

View full text Add to dashboard Cite

show abstract

“…In schizophrenic patients, direct measures of SAM have been carried out by Andreoli and Maffei (1975). They reported a 50% reduction in acute schizo-phrenics compared with normal controls.…”

Section: Discussionmentioning

confidence: 99%

Homocysteinemia and schizophrenia as a case of methylation deficiency

Regland

Johansson

Gottfries

1994

J. Neural Transmission

View full text Add to dashboard Cite

A 27-year-old woman is described whose disorder meets the DSM-III-R criteria for a diagnosis of schizophrenia and who was found to have a significantly increased serum level of homocysteine. Repeatedly, she improved on frequent cobalamin injections and deteriorated in periods without treatment. The effects of prolonged weekly treatment appeared to diminish as time went on, suggesting that the abnormality was not wholly cobalamin-dependent. It was found that methylenetetrahydrofolate reductase (MR) activity in cultured skin fibroblasts was reduced to a magnitude that is found among people with heterozygous deficiency. A defect in MR activity indicates a deficiency in methyltetrahydrofolate (MTHF), with a consequent reduction of the remethylation of homocysteine to methionine. Thus, reduced methylation may explain the increased levels of homocysteine and the transient effects of cobalamin treatment in the patient. Theoretically, MTHF should be the optimal treatment for her. The case reported highlights the importance of assessing the serum homocysteine level in order to detect methylation deficiency in patients with schizophrenia.

show abstract

“…A single pathophysiologic process may account for this diversity, but there is also the possibility that the syndrome comprises several disease processes, each with its own manifestations. There are studies suggesting that a substantial proportion of schizophrenic patients have an abnormal methyl metabolism (Andreoli et al, 1975;Smythies et al, 1986;Sargent et al, 1992). We recently described the case of a female schizophrenic who had a significantly raised level of homocysteine in serum as the probable marker of insufficient methylation, a notion supported by her reduced activity of the enzyme methylenetetrahydrofolate reductase (MR) and the fact that she responded favourably to cobalamin treatment (Regland et al, 1994).…”

Section: Introductionmentioning

confidence: 99%